Kelyniam Global to Present at Planet MicroCap Las Vegas 2026 - From Single Product to Regenerative Medicine Leader
Kelyniam CEO
"Kelyniam is hitting this conference for the first time," said
Key Highlights:
- Fusion™ Implant Launch: FDA-cleared BCP-PEEK implant – the first new material approved in the
U.S . cranial market in eight years, combining strength with superior bone integration and 24-48 hour delivery. The first implant was delivered in April. - Regenerative Leadership: The only company offering neurosurgeons a full portfolio including Fusion™ BCP-PEEK, CustomizedBone™ hydroxyapatite (the only pediatric option for children as young as seven), and Osteopore polycaprolactone products.
- Financial Momentum: Q1 2026 revenue of
$1.15 million (+84% YoY), gross profit +105%, and operating income of$295,295 . - Strategic Acceleration: Expanded licensing agreements, new development partnerships, and the addition of veteran medical device leader
Kris Renton as Chief Revenue Officer.
The presentation will showcase Kelyniam's differentiated regenerative platform, rapid manufacturing edge, and clear path to sustained growth in the expanding cranial reconstruction market.
About Kelyniam Global, Inc. Kelyniam Global, Inc. (OTC: KLYG) specializes in the rapid production of patient-specific cranial and craniofacial implants using advanced CAD/CAM technology and next-generation biomaterials. Renowned for industry-leading 24-48 hour turnaround, Kelyniam partners with neurosurgeons to deliver superior clinical and economic outcomes. For more information, visit www.kelyniam.com.
Cautionary Note Regarding Forward-Looking Statements This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially due to risks and uncertainties. Please refer to Kelyniam's SEC filings for more details.
View original content:https://www.prnewswire.com/news-releases/kelyniam-global-to-present-at-planet-microcap-las-vegas-2026--from-single-product-to-regenerative-medicine-leader-302786273.html
SOURCE Kelyniam Global Inc
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Arcus, AVEO to test kidney cancer drug combo in new trial
- Hyliion wins $41.7M Navy contract for KARNO power systems
- Southern Cross Acquisition closes $115M IPO on Nasdaq
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share